Mayday University Hospital awarded 3 stars in NHS performance rating

Posted:
4
August 2005

Unit At Mayday

We are delighted to announce that Mayday University Hospital NHS Trust was recently issued an annual performance rating of 3 stars, which places them in the top 28% of Trusts in the UK. This is the highest rating available under the Healthcare Commission rating scheme.The performance rating reports are designed to review the key factors the Trusts need to achieve to deliver a better service to patients. This includes Patient Focus, Clinical Focus, Capacity and Capability Focus, Access to Quality Services, Improving Health and Services Provision. Overall, the Healthcare Commission report concluded that Mayday Hospital is delivering in each of these areas.Dr Jörg Täubel, Managing Director of Richmond Pharmacology, commented: “We have been working closely with the Trust over the past 18 months to facilitate the move of our second unit to Mayday hospital. Throughout this period of time I have been consistently impressed with the quality I experienced when working with the Trust. I am very pleased that this standard has been recognized by the Healthcare Commission. It's reassuring to conduct our trials within such a well managed, acute setting.”Richmond opened the new unit within Mayday University Hospital in May 2005.To view the Healthcare Commission report on Mayday click here.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more